Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Prevalence of High Tumor Mutational Burden Among Pediatric Patients With Solid Tumors.
Journal: Pediatric hematology and oncology
Published: August 31, 2026
Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.
Journal: Journal of neuro-oncology
Published: November 25, 2025
Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Journal: The New England journal of medicine
Published: October 22, 2025
Prevalence of Homologous Recombination Repair Mutations and Association with Clinical Outcomes in Patients with Solid Tumors: A Study Using the AACR Project GENIE Dataset.
Journal: Cancers
Published: December 17, 2024
Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis.
Journal: Advances in therapy
Published: November 27, 2024
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
Journal: Gynecologic oncology
Published: September 24, 2024
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study.
Journal: Future oncology (London, England)
Published: July 16, 2024
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis.
Journal: Future oncology (London, England)
Published: February 14, 2024
Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors.
Journal: JCO precision oncology
Published: November 16, 2023
Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study.
Journal: Advances in therapy
Published: August 29, 2023
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.
Journal: Nature cancer
Published: August 03, 2023
Last Updated: 09/26/2026